Medindia

X

NTT DATA Extends DATATRAK Relationship

Wednesday, June 1, 2011 General News J E 4
Advertisement
NTT to Introduce a Branded Version of DATATRAK eClinical® for the Japanese PMS Market

CLEVELAND, June 1, 2011 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of a five-year extension to the Enterprise Agreement and Marketing Alliance with NTT DATA Corporation. In addition, DATATRAK has agreed to extend its product's capabilities in Post Marketing Studies and is adapting related functionalities in response to demands from the Japanese clinical trials market. The multi-year, multi-million dollar extension and development agreement allows NTT DATA to continue to be a value-added-reseller of DATATRAK eClinical® and to sell Enterprise Transfer services within the Japanese market.

The relationship consists of a five-year enterprise subscription license agreement through which NTT DATA continues to standardize on the DATATRAK unified platform for designing and delivering electronic clinical trials. The extension and development agreement was paid in full in accordance with the terms of the agreement and has the potential to increase in value as additional products and services provided by DATATRAK are contracted on an as needed basis.

"NTT DATA continues to be a successful strategic partner, and we are excited to assist in the delivery of DATATRAK eClinical® as they expand into the Japanese PMS market," said Laurence P. Birch, DATATRAK's Chairman of the Board and CEO. "The renewal of the Enterprise Agreement not only validates DATATRAK's capabilities and effectiveness throughout international markets, but more importantly, it strengthens our financial position providing us the ability to fund additional growth opportunities and protect our intellectual property."

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services™ group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and devices studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the OTCQX Market announcing its results for the three-month period ending March 31, 2011. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
TPI Receives Production License for Its Anti-diabe...
S
Reportlinker Adds Hearing Aid Devices - Global Pip...